Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
Go back to Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease| Johnson & Johnson (NYSE: JNJ) | Delayed: 231.29 +2.90 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.39 | 52 Week High | $126.07 | |||
| Open | $228.95 | 52 Week Low | $94.28 | |||
| Day High | $231.45 | P/E | 48.09 | |||
| Day Low | $227.50 | EPS | $4.81 | |||
| Volume | 8,516,520 | |||||
